Clinical Trial Search

Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL

Primary: Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir — 239.9; 257.6; 282; 350 mg/dL — p=<0.05

Primary: Change From Baseline Triglycerides — 125 units on a scale

Primary: Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels — 0; 0; -0.03; -0.08 Log10 copies/ml plasma

Primary: Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group. — -34; 40 mg/dl — p=0.01

Primary: Percent Change From Baseline in LDL-C at Week 24 — 1.68; -55.23 percent change — p=< 0.0001

Primary: Absolute Change in Relative FMD (%) — 0.60; 0.50 % FMD — p=0.28

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Patients With Low-density Lipoprotein (LDL) Cholesterol Reduction — 90.9 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants

Primary: LDL Cholesterol — 116.34; 118.84 mg/dl

Primary: Proportion of Subjects With Triglycerides <200 mg/dL — 12 participants

Primary: The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both…

Primary: Change in Baseline Mean Serum Triglyceride Level at Study End — -103.0; -23.4 mg/dl

Primary: Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 — -0.08; -0.08 log10 pg/mL — p=0.94

Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h

Primary: Percentage Change From Baseline in Total Cholesterol at 12 Weeks. — 8.7; 21.4 Percentage Change (%) — p=0.003

Primary: Bone Mineral Density (BMD) — -0.03; -0.53 percentage of change

Primary: The GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response…

Primary: Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12 — 113.7; 114.2; 22.0; 8.1 milligram per deciliters (mg/dL)

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Changes in the Inflammatory Marker IL-6 — 42.5; 40.0; 39.3; 41.1 pg/mL

Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48 — 0.02; -0.02; 0.02; -0.01 ratio — p=0.48

Primary: Change From Baseline to Week 12 in Fasting Triglycerides — -0.5; -0.1 mmol/L — p=0.034

Primary: Gemfibrozil Area Under the Concentration vs. Time Curve (AUC) — 104; 62 ng*hr/mL — p=<0.0001

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily — 60; 21 percentage change in activated T-cells — p=<0.05